Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 23 Show results per page	View Search Criteria \| Help With Results

Last Modified: 8/1/1999 First Published: 12/1/1997


1.		Phase II Study of Fazarabine and Filgrastim (G-CSF) in Chemotherapy Naive Patients with Recurrent or Metastatic Adenocarcinoma of the Pancreas (Summary Last Modified 08/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				NCCTG-964351 NCCTG-96-43-51

Last Modified: 11/1/1991


2.		Phase II Trial of Fazarabine in Patients with Refractory Metastatic and/or Unresectable Cancers of the Breast, Colon, and Testis (Summary Last Modified 11/91)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				over 18				NCI				NCI-89-C-105 NCI-MB-241, NCI-T89-0045N, T89-0045

Last Modified: 1/1/1990


3.		Phase II Study of Fazarabine in Patients with Persistent or Recurrent Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 01/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				any age				NCI				SWOG-8912 SWOG-8912

Last Modified: 10/1/1989


4.		Phase II Study of Fazarabine in Patients with Metastatic Breast Cancer (Summary Last Modified 10/89)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				MDA-DM-89052 NCI-T89-0122C, T89-0122

Last Modified: 7/1/1990


5.		Phase II Master Protocol for Advanced, Recurrent Pelvic Gynecologic Malignancies: Fazarabine (Summary Last Modified 07/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				any age				NCI				GOG-26GG GOG-26GG

Last Modified: 6/1/1997


6.		Phase II Study of Fazarabine in Patients with Advanced Measurable Colorectal Cancer (Summary Last Modified 06/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				MDA-DM-89107 NCI-T89-0212C, T89-0212

Last Modified: 7/1/1990


7.		Phase II Trial of Fazarabine in Patients with Metastatic Pancreatic or Periampullary Adenocarcinoma (Summary Last Modified 07/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				MSKCC-90007 NCI-T90-0021C, T90-0021

Last Modified: 8/1/1990


8.		Phase II Study of Fazarabine in Patients with CNS Tumors (Summary Last Modified 08/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				no age specified				NCI				SWOG-8834 SWOG-8834

Last Modified: 10/1/1991


9.		Phase II Study of Intravenous Fazarabine in Patients with Advanced non-Small Cell Lung Cancer (Summary Last Modified 10/91)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				MAYO-902401 NCI-T90-0062C, T90-0062

Last Modified: 5/3/2007


10.		Phase II Study of Fazarabine in Children with Recurrent Solid Tumors (Summary Last Modified 08/91)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				under 21 at diagnosis				NCI				CCG-0902 CCG-0902

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute